Biosimilars in Italy: a new regime
10-01-2017
Biosimilar cost savings yet to materialise, says healthcare organisation
26-08-2016
roschetzky / iStockphoto
Introducing more biosimilars could cut healthcare spending by $54 billion over the next ten years, a figure far higher than initially thought, a think tank and research organisation has claimed.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Rand Corporation, biosimilars, biologics, "Biosimilar Cost Savings in the US”; Zarxio, Amgen, Sandoz
